

Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others), By Treatment (Medication, Surgery, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition

<https://marketpublishers.com/r/A9E6507397FBEN.html>

Date: October 2023

Pages: 183

Price: US\$ 4,900.00 (Single User License)

ID: A9E6507397FBEN

Abstracts

Global Atherosclerosis Drugs Market has valued at USD 18.27 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 2.43% through 2028. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to the accumulation of fatty deposits, remains a major global health concern. It is a leading cause of heart disease, stroke, and other cardiovascular complications, contributing to millions of deaths annually. The Global Atherosclerosis Drugs Market, driven by the increasing prevalence of this condition, has witnessed significant growth in recent years.

Atherosclerosis is increasingly prevalent worldwide, mainly due to unhealthy lifestyles, including poor diet, lack of physical activity, and smoking. This has created a substantial patient pool in need of treatment and management. The aging global population is at a higher risk of atherosclerosis. As the elderly demographic grows, so does the demand for atherosclerosis drugs. Advancements in medical technology and diagnostics have enabled early detection of atherosclerosis, promoting timely intervention and medication. Public awareness campaigns and educational efforts have made people

more conscious of their cardiovascular health, leading to more individuals seeking treatment.

The Global Atherosclerosis Drugs Market presents both opportunities and challenges. As the burden of atherosclerosis continues to rise, innovation and research are crucial in developing effective treatments. Personalized medicine and targeted therapies hold promise in improving patient outcomes. However, addressing issues related to drug pricing, adherence, and emerging competition will be essential to ensure that atherosclerosis drugs remain accessible to those in need. Ultimately, the collaboration of pharmaceutical companies, healthcare providers, and policymakers is essential in the fight against atherosclerosis and its devastating consequences on global health.

Key Market Drivers

Rising Prevalence of Atherosclerosis is Driving the Global Atherosclerosis Drugs Market

Atherosclerosis, a condition characterized by the build-up of plaque in arteries, is becoming increasingly prevalent worldwide. This arterial disease poses significant health risks, including heart attacks and strokes, making it a global healthcare concern. Consequently, the global atherosclerosis drugs market is on the rise, driven by the growing need for effective treatments. Modern lifestyles often involve long hours of sitting, reduced physical activity, and poor dietary choices. These factors contribute to obesity, hypertension, and elevated cholesterol levels, all of which increase the risk of atherosclerosis.

Diets high in saturated fats, trans fats, and processed foods are common in many parts of the world. These diets not only contribute to obesity but also raise the levels of LDL (low-density lipoprotein) cholesterol, a major risk factor for atherosclerosis. Atherosclerosis is more prevalent among older individuals. As the global population ages, the incidence of atherosclerosis is expected to increase, placing additional strain on healthcare systems. Tobacco use remains a significant risk factor for atherosclerosis. Despite public health campaigns to reduce smoking rates, many individuals continue to smoke, further exacerbating the problem. Diabetes is associated with a higher risk of atherosclerosis due to elevated blood sugar levels and other metabolic changes. The rising prevalence of diabetes worldwide contributes to the increasing incidence of atherosclerosis.

The rising prevalence of atherosclerosis has led to a growing demand for effective treatments, which, in turn, is driving the global atherosclerosis drugs market. Several

factors are contributing to the market's expansion. Pharmaceutical companies are investing heavily in research and development to create innovative drugs for atherosclerosis treatment. These efforts aim to develop more effective medications with fewer side effects. Public awareness campaigns and educational initiatives are helping individuals recognize the risk factors and symptoms of atherosclerosis, leading to earlier diagnosis and treatment. Lifestyle modifications, including diet and exercise, play a crucial role in managing atherosclerosis. This has spurred the development of complementary products and services, such as dietary supplements and fitness programs, which are also contributing to the market's growth. Technological advancements in diagnostic imaging techniques, such as CT scans and angiography, allow for earlier and more accurate detection of atherosclerosis, facilitating timely intervention and treatment. Collaboration between pharmaceutical companies, healthcare providers, and research institutions is fostering innovation and the development of comprehensive treatment approaches.

Increasing Geriatric Population is Driving the Global Atherosclerosis Drugs Market

The global healthcare landscape is witnessing a significant transformation as the world's population ages. One of the key health concerns associated with aging is atherosclerosis, a condition characterized by the buildup of plaque in the arteries, leading to various cardiovascular diseases. As the aging population continues to grow, the demand for atherosclerosis drugs is on the rise, propelling the global atherosclerosis drugs market to new heights. The global population is aging at an unprecedented rate. According to the World Health Organization (WHO), the proportion of people aged 60 and over is expected to double by 2050, accounting for 22% of the world's population. As individuals age, their risk of developing atherosclerosis and related cardiovascular conditions significantly increases. This demographic shift is a primary driver behind the growing demand for atherosclerosis drugs.

With atherosclerosis as a key contributor to heart attacks, strokes, and other cardiovascular diseases, the rising aging population directly correlates with an increased incidence of these conditions. This necessitates a greater need for effective atherosclerosis drugs. Advances in healthcare, nutrition, and lifestyle have contributed to longer life expectancy. While this is undoubtedly a positive development, it also means that individuals are exposed to the risk of atherosclerosis and its complications for a more extended period, further fueling the demand for treatment options. Aging is associated with various risk factors for atherosclerosis, such as hypertension, diabetes, and high cholesterol levels. As the population ages, the prevalence of these risk factors rises, underscoring the need for pharmacological interventions.

Pharmaceutical companies are exploring novel therapeutic approaches to manage atherosclerosis. These include targeted therapies that aim to reduce plaque buildup and inflammation within arterial walls. Advancements in genomics and personalized medicine are enabling healthcare providers to tailor atherosclerosis treatments to individual patients, optimizing efficacy and minimizing side effects. Researchers are investigating combinations of drugs with complementary mechanisms of action to enhance treatment outcomes and reduce the risk of disease progression.

Pharmaceutical companies are also investing in educational initiatives to raise awareness about atherosclerosis risk factors and prevention strategies, emphasizing the importance of a healthy lifestyle.

Key Market Challenges

Regulatory Barriers

One of the most significant hurdles for the atherosclerosis drugs market is the stringent regulatory framework governing the approval of new drugs. Regulatory authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require extensive clinical trials to demonstrate both the safety and efficacy of new drugs. This process is not only time-consuming but also costly. Moreover, the bar for proving effectiveness is continually raised, making it more challenging for pharmaceutical companies to bring new therapies to market.

Increasing Competition

The atherosclerosis drugs market is fiercely competitive, with numerous pharmaceutical companies vying for market share. Established players, such as Pfizer and AstraZeneca, dominate the market with well-established drugs like Lipitor and Crestor. Entering this market and gaining a foothold can be challenging for newer, smaller companies, particularly when dealing with the complex regulatory landscape and the need for significant financial resources.

Intellectual Property Concerns

Pharmaceutical companies invest heavily in research and development to create innovative atherosclerosis drugs. Protecting their intellectual property through patents is crucial, as it provides exclusivity for a certain period, allowing them to recoup their investments. However, once patents expire, generic versions of the drugs become

available, leading to reduced revenues for the original manufacturers. Navigating the complex landscape of patents, generic competition, and exclusivity rights poses an ongoing challenge for companies in this market.

Evolving Treatment Paradigms

Advancements in medical research and technology have led to evolving treatment paradigms in atherosclerosis management. Lifestyle modifications, such as dietary changes and increased physical activity, are often recommended as initial interventions. This shift toward prevention and early intervention can potentially reduce the need for drug therapies, impacting the growth of the atherosclerosis drugs market.

Price Pressures and Healthcare Costs

Atherosclerosis drugs, especially newer and more advanced therapies, can be expensive. As healthcare costs continue to rise globally, payers, including government healthcare systems and private insurers, are putting pressure on drug manufacturers to lower prices. This creates a challenge for pharmaceutical companies to balance the need for profitability with the demand for more affordable medications.

Patient Adherence

Atherosclerosis drugs are often prescribed for long periods, sometimes even for life. Patient adherence to medication regimens is crucial for achieving positive treatment outcomes. However, ensuring that patients consistently take their prescribed medications can be challenging. Factors such as forgetfulness, cost, and concerns about side effects can all contribute to poor adherence rates.

Key Market Trends

Technological Advancements

Atherosclerosis, a chronic condition characterized by the buildup of plaque in arteries, has long been a significant health concern worldwide. It is a leading cause of heart disease, strokes, and other cardiovascular diseases, contributing to millions of deaths annually. However, with the relentless march of technological advancements in the healthcare sector, there is newfound hope for combating atherosclerosis. These innovations are revolutionizing the development, diagnosis, and treatment of atherosclerosis, which in turn is driving the growth of the global atherosclerosis drugs

market.

Modern imaging technologies like CT angiography, magnetic resonance imaging (MRI), and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, allowing healthcare professionals to visualize plaque buildup and assess its severity accurately. Blood tests now incorporate biomarkers that can detect specific molecules associated with atherosclerosis, such as high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2). These tests aid in early detection and risk assessment. AI and machine learning algorithms are being employed to analyze medical imaging and patient data, helping to identify patterns and predict atherosclerosis development. This technology enhances the efficiency and accuracy of diagnosis.

Advances in pharmacogenomics and personalized medicine are enabling the development of drugs that target specific genetic markers associated with atherosclerosis, improving treatment efficacy and minimizing side effects. Nanoparticles are being utilized to deliver drugs directly to arterial plaques, enhancing drug effectiveness while minimizing systemic side effects. Technological innovations have led to the development of drug-eluting stents, which are coated with medications that prevent restenosis (re-narrowing of arteries) after angioplasty and stent placement. Cutting-edge gene-editing techniques like CRISPR-Cas9 hold the potential to address the genetic factors contributing to atherosclerosis, opening up new avenues for treatment development.

Telehealth platforms and wearable devices enable healthcare providers to remotely monitor patients with atherosclerosis, allowing for early intervention and reducing hospitalization rates. Mobile applications and wearable devices can track vital signs, physical activity, and dietary habits, empowering patients to take a proactive role in managing their condition. The analysis of large datasets is providing valuable insights into atherosclerosis epidemiology, treatment outcomes, and patient responses, helping refine treatment approaches.

Segmental Insights

Route of Administration Insights

Based on the category of Route of Administration, Oral emerged as the dominant player in the global market for Atherosclerosis Drugs in 2022. The oral route of administration, where medications are taken by mouth in the form of tablets, capsules, or liquids, has

emerged as the preferred choice for atherosclerosis drugs for several compelling reasons. One of the primary advantages of the oral route is its simplicity and ease of use. Patients can take medications at home without the need for medical supervision or invasive procedures. This convenience often leads to better adherence to treatment regimens, improving overall patient outcomes. Patients are generally more receptive to oral medications because they are familiar with this method. This ease of acceptance can lead to increased patient compliance, a critical factor in managing chronic conditions like atherosclerosis. Oral medications can be formulated in various ways, including extended-release formulations that provide continuous drug delivery over time. This allows for tailored treatment plans to meet individual patient needs. Oral medications tend to be more cost-effective than other routes of administration, such as intravenous or transdermal options. This affordability can make treatment more accessible to a broader range of patients. Pharmaceutical companies often focus their research and development efforts on oral formulations due to their wide market appeal. This results in a more extensive selection of oral atherosclerosis drugs and innovative formulations. The oral route typically presents fewer side effects compared to other administration methods, such as injections. This can enhance the overall patient experience and treatment compliance.

End User Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are at the forefront of diagnosing and treating atherosclerosis. They serve as the primary points of contact for patients experiencing cardiovascular symptoms and are essential in managing this condition effectively. Hospitals and clinics play a critical role in diagnosing atherosclerosis through various methods, including imaging techniques like angiography, ultrasound, and CT scans. Early detection is vital for initiating appropriate treatment. Once diagnosed, patients often require medical intervention to manage their atherosclerosis. Hospitals provide a wide range of treatment options, including medication and surgical procedures such as angioplasty or coronary artery bypass grafting (CABG). After surgical procedures or severe cardiac events, hospitals offer rehabilitation programs to help patients recover and prevent the progression of atherosclerosis. These programs include lifestyle modifications, exercise regimens, and dietary counseling. Hospitals and clinics are also crucial in dispensing atherosclerosis drugs to patients. Statins, antiplatelet medications, and antihypertensive drugs are commonly prescribed to manage atherosclerosis and reduce the risk of complications.

Regional Insights

North America emerged as the dominant player in the global Atherosclerosis Drugs market in 2022, holding the largest market share in terms of value. One of the primary reasons behind North America's dominance in the global atherosclerosis drugs market is the high incidence of atherosclerosis in the region. Factors such as a sedentary lifestyle, unhealthy dietary habits, and a growing aging population have contributed to a significant prevalence of atherosclerotic diseases, including coronary artery disease and peripheral artery disease. This high disease burden has led to a substantial demand for atherosclerosis drugs. North America boasts a well-developed and advanced healthcare infrastructure. The region is home to some of the world's leading pharmaceutical companies, research institutions, and healthcare providers. This infrastructure enables the efficient development, testing, and distribution of atherosclerosis drugs, fostering innovation and driving market growth. North America invests heavily in research and development (R&D) activities related to atherosclerosis drugs. Pharmaceutical companies in the United States and Canada dedicate substantial resources to discover and develop novel therapies for atherosclerosis. These investments not only drive product innovation but also enhance the competitiveness of the North American market in the global arena.

Key Market Players

F. Hoffmann-La Roche Ltd.

Mylan N.V.

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

Pfizer Inc.

GlaxoSmithKline plc

Novartis AG

Merck & Co

Allergan Plc

AstraZeneca

Report Scope:

In this report, the Global Atherosclerosis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Atherosclerosis Drugs Market, By Diagnosis:

Ankle-brachial Index

Doppler Ultrasound

Echocardiogram Electrocardiogram Blood Tests

Others

Atherosclerosis Drugs Market, By Treatment :

Medication

Surgery

Others

Atherosclerosis Drugs Market, By Route of Administration:

Oral

Parenteral

Others

Atherosclerosis Drugs Market, By End user:

Hospitals & Clinics

Ambulatory Care Centers

Others

Atherosclerosis Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Atherosclerosis Drugs Market.

Available Customizations:

Global Atherosclerosis Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Treatment
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validations
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
 - 5.2.2. By Treatment (Medication, Surgery, Others)

- 5.2.3. By Route of Administration (Oral, Parenteral, Others)
- 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.5. By Region
- 5.2.6. By Company (Shares of Top 5 Market Players)
- 5.3. Market Map
 - 5.3.1. By Diagnosis
 - 5.3.2. By Treatment
 - 5.3.3. By Route of Administration
 - 5.3.4. By End User
 - 5.3.5. By Region

6. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Diagnosis
 - 6.2.2. By Treatment
 - 6.2.3. By Route of Administration
 - 6.2.4. By End User
 - 6.2.5. By Country
 - 6.2.5.1. United States Atherosclerosis Drugs Market Outlook
 - 6.2.5.1.1. Market Size & Forecast
 - 6.2.5.1.1.1. By Value
 - 6.2.5.1.2. Market Share & Forecast
 - 6.2.5.1.2.1. By Diagnosis
 - 6.2.5.1.2.2. By Treatment
 - 6.2.5.1.2.3. By Route of Administration
 - 6.2.5.1.2.4. By End User
 - 6.2.5.2. Canada Atherosclerosis Drugs Market Outlook
 - 6.2.5.2.1. Market Size & Forecast
 - 6.2.5.2.1.1. By Value
 - 6.2.5.2.2. Market Share & Forecast
 - 6.2.5.2.2.1. By Diagnosis
 - 6.2.5.2.2.2. By Treatment
 - 6.2.5.2.2.3. By Route of Administration
 - 6.2.5.2.2.4. By End User
 - 6.2.5.3. Mexico Atherosclerosis Drugs Market Outlook
 - 6.2.5.3.1. Market Size & Forecast

- 6.2.5.3.1.1. By Value
- 6.2.5.3.2. Market Share & Forecast
 - 6.2.5.3.2.1. By Diagnosis
 - 6.2.5.3.2.2. By Treatment
 - 6.2.5.3.2.3. By Route of Administration
 - 6.2.5.3.2.4. By End User

7. EUROPE ATHEROSCLEROSIS DRUGS MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Diagnosis
 - 7.2.2. By Treatment
 - 7.2.3. By Route of Administration
 - 7.2.4. By End User
 - 7.2.5. By Country
 - 7.2.5.1. France Atherosclerosis Drugs Market Outlook
 - 7.2.5.1.1. Market Size & Forecast
 - 7.2.5.1.1.1. By Value
 - 7.2.5.1.2. Market Share & Forecast
 - 7.2.5.1.2.1. By Diagnosis
 - 7.2.5.1.2.2. By Treatment
 - 7.2.5.1.2.3. By Route of Administration
 - 7.2.5.1.2.4. By End User
 - 7.2.5.2. Germany Atherosclerosis Drugs Market Outlook
 - 7.2.5.2.1. Market Size & Forecast
 - 7.2.5.2.1.1. By Value
 - 7.2.5.2.2. Market Share & Forecast
 - 7.2.5.2.2.1. By Diagnosis
 - 7.2.5.2.2.2. By Treatment
 - 7.2.5.2.2.3. By Route of Administration
 - 7.2.5.2.2.4. By End User
 - 7.2.5.3. United Kingdom Atherosclerosis Drugs Market Outlook
 - 7.2.5.3.1. Market Size & Forecast
 - 7.2.5.3.1.1. By Value
 - 7.2.5.3.2. Market Share & Forecast
 - 7.2.5.3.2.1. By Diagnosis
 - 7.2.5.3.2.2. By Treatment

- 7.2.5.3.2.3. By Route of Administration
- 7.2.5.3.2.4. By End User
- 7.2.5.4. Italy Atherosclerosis Drugs Market Outlook
 - 7.2.5.4.1. Market Size & Forecast
 - 7.2.5.4.1.1. By Value
 - 7.2.5.4.2. Market Share & Forecast
 - 7.2.5.4.2.1. By Diagnosis
 - 7.2.5.4.2.2. By Treatment
 - 7.2.5.4.2.3. By Route of Administration
 - 7.2.5.4.2.4. By End User
- 7.2.5.5. Spain Atherosclerosis Drugs Market Outlook
 - 7.2.5.5.1. Market Size & Forecast
 - 7.2.5.5.1.1. By Value
 - 7.2.5.5.2. Market Share & Forecast
 - 7.2.5.5.2.1. By Diagnosis
 - 7.2.5.5.2.2. By Treatment
 - 7.2.5.5.2.3. By Route of Administration
 - 7.2.5.5.2.4. By End User

8. ASIA PACIFIC ATHEROSCLEROSIS DRUGS MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By Diagnosis
 - 8.2.2. By Treatment
 - 8.2.3. By Route of Administration
 - 8.2.4. By End User
 - 8.2.5. By Country
 - 8.2.5.1. China Atherosclerosis Drugs Market Outlook
 - 8.2.5.1.1. Market Size & Forecast
 - 8.2.5.1.1.1. By Value
 - 8.2.5.1.2. Market Share & Forecast
 - 8.2.5.1.2.1. By Diagnosis
 - 8.2.5.1.2.2. By Treatment
 - 8.2.5.1.2.3. By Route of Administration
 - 8.2.5.1.2.4. By End User
 - 8.2.5.2. India Atherosclerosis Drugs Market Outlook
 - 8.2.5.2.1. Market Size & Forecast

- 8.2.5.2.1.1. By Value
- 8.2.5.2.2. Market Share & Forecast
 - 8.2.5.2.2.1. By Diagnosis
 - 8.2.5.2.2.2. By Treatment
 - 8.2.5.2.2.3. By Route of Administration
 - 8.2.5.2.2.4. By End User
- 8.2.5.3. South Korea Atherosclerosis Drugs Market Outlook
 - 8.2.5.3.1. Market Size & Forecast
 - 8.2.5.3.1.1. By Value
 - 8.2.5.3.2. Market Share & Forecast
 - 8.2.5.3.2.1. By Diagnosis
 - 8.2.5.3.2.2. By Treatment
 - 8.2.5.3.2.3. By Route of Administration
 - 8.2.5.3.2.4. By End User
- 8.2.5.4. Japan Atherosclerosis Drugs Market Outlook
 - 8.2.5.4.1. Market Size & Forecast
 - 8.2.5.4.1.1. By Value
 - 8.2.5.4.2. Market Share & Forecast
 - 8.2.5.4.2.1. By Diagnosis
 - 8.2.5.4.2.2. By Treatment
 - 8.2.5.4.2.3. By Route of Administration
 - 8.2.5.4.2.4. By End User
- 8.2.5.5. Australia Atherosclerosis Drugs Market Outlook
 - 8.2.5.5.1. Market Size & Forecast
 - 8.2.5.5.1.1. By Value
 - 8.2.5.5.2. Market Share & Forecast
 - 8.2.5.5.2.1. By Diagnosis
 - 8.2.5.5.2.2. By Treatment
 - 8.2.5.5.2.3. By Route of Administration
 - 8.2.5.5.2.4. By End User

9. SOUTH AMERICA ATHEROSCLEROSIS DRUGS MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast
 - 9.2.1. By Diagnosis
 - 9.2.2. By Treatment
 - 9.2.3. By Route of Administration

9.2.4. By End User

9.2.5. By Country

9.2.5.1. Brazil Atherosclerosis Drugs Market Outlook

9.2.5.1.1. Market Size & Forecast

9.2.5.1.1.1. By Value

9.2.5.1.2. Market Share & Forecast

9.2.5.1.2.1. By Diagnosis

9.2.5.1.2.2. By Treatment

9.2.5.1.2.3. By Route of Administration

9.2.5.1.2.4. By End User

9.2.5.2. Argentina Atherosclerosis Drugs Market Outlook

9.2.5.2.1. Market Size & Forecast

9.2.5.2.1.1. By Value

9.2.5.2.2. Market Share & Forecast

9.2.5.2.2.1. By Diagnosis

9.2.5.2.2.2. By Treatment

9.2.5.2.2.3. By Route of Administration

9.2.5.2.2.4. By End User

9.2.5.3. Colombia Atherosclerosis Drugs Market Outlook

9.2.5.3.1. Market Size & Forecast

9.2.5.3.1.1. By Value

9.2.5.3.2. Market Share & Forecast

9.2.5.3.2.1. By Diagnosis

9.2.5.3.2.2. By Treatment

9.2.5.3.2.3. By Route of Administration

9.2.5.3.2.4. By End User

10. MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Diagnosis

10.2.2. By Treatment

10.2.3. By Route of Administration

10.2.4. By End User

10.2.5. By Country

10.2.5.1. South Africa Atherosclerosis Drugs Market Outlook

10.2.5.1.1. Market Size & Forecast

- 10.2.5.1.1.1. By Value
- 10.2.5.1.2. Market Share & Forecast
 - 10.2.5.1.2.1. By Diagnosis
 - 10.2.5.1.2.2. By Treatment
 - 10.2.5.1.2.3. By Route of Administration
 - 10.2.5.1.2.4. By End User
- 10.2.5.2. Saudi Arabia Atherosclerosis Drugs Market Outlook
 - 10.2.5.2.1. Market Size & Forecast
 - 10.2.5.2.1.1. By Value
 - 10.2.5.2.2. Market Share & Forecast
 - 10.2.5.2.2.1. By Diagnosis
 - 10.2.5.2.2.2. By Treatment
 - 10.2.5.2.2.3. By Route of Administration
 - 10.2.5.2.2.4. By End User
- 10.2.5.3. UAE Atherosclerosis Drugs Market Outlook
 - 10.2.5.3.1. Market Size & Forecast
 - 10.2.5.3.1.1. By Value
 - 10.2.5.3.2. Market Share & Forecast
 - 10.2.5.3.2.1. By Diagnosis
 - 10.2.5.3.2.2. By Treatment
 - 10.2.5.3.2.3. By Route of Administration
 - 10.2.5.3.2.4. By End User

11. MARKET DYNAMICS

- 11.1. Drivers
- 11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Technology Launches

13. COMPETITIVE LANDSCAPE

- 13.1. F. Hoffmann-La Roche Ltd.
 - 13.1.1. Business Overview
 - 13.1.2. Patient Offerings

- 13.1.3. Recent Developments
- 13.1.4. Key Personnel
- 13.1.5. SWOT Analysis
- 13.2. Mylan N.V.
- 13.3. Teva Pharmaceutical Industries Ltd.
- 13.4. Sanofi India
- 13.5. Pfizer Inc.
- 13.6. GlaxoSmithKline plc
- 13.7. Novartis AG
- 13.8. Merck & Co
- 13.9. Allergan India Pvt Ltd.
- 13.10. AstraZeneca

14. STRATEGIC RECOMMENDATIONS

About us & Disclaimer

I would like to order

Product name: Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others), By Treatment (Medication, Surgery, Others), By Route of Administration (Oral, Parenteral, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition

Product link: <https://marketpublishers.com/r/A9E6507397FBEN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A9E6507397FBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970